Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

King Tigan Suppository sNDA Pushed To 2004 Under Revised FDA Agreement

Executive Summary

King has an additional two years to submit an sNDA for Tigan suppositories under an amended agreement with FDA requiring submission by December 2004

You may also be interested in...



No Rest For Sonata: King To Develop XR Version After Acquisition From Elan

King plans to develop an extended-release version of Sonata following an $850 mil. acquisition of Elan's primary care business

No Rest For Sonata: King To Develop XR Version After Acquisition From Elan

King plans to develop an extended-release version of Sonata following an $850 mil. acquisition of Elan's primary care business

Synthroid Sales Expected To Grow 12% For Year Following NDA Approval

Abbott expects Synthroid growth of approximately 12% in 2002 following approval of the synthetic thyroid hormone replacement therapy's NDA

Related Content

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel